GUB014295
Sources
registry, as of 2026-01-15Stale
https://clinicaltrials.gov/study/NCT06144684
A Two-Part First-In-Human Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GUB014295. Overall status COMPLETED. Phases PHASE1. Lead sponsor AbbVie. Enrollment 76. Conditions Healthy Volunteers; Overweight. This is a two-part, single centre, double-blind (within cohorts), randomised, placebo-controlled, single (Part 1) and multiple (Part 2) ascending subcutaneous dose study in lean to overweight or obese but otherwise healthy men (Part 1) and men and non-pregnant, non-lactating wome
ClinicalTrials.gov NCT06144684 protocol and results modules